Integra LifeSciences (NASDAQ:IART) Issues Q1 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its first quarter 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.400-0.450 for the period, compared to the consensus estimate of 0.560. The company issued revenue guidance of $375.0 million-$385.0 million, compared to the consensus revenue estimate of $411.7 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IART. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley started coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Stock Up 10.5 %

Shares of NASDAQ IART traded up $2.31 during trading hours on Tuesday, hitting $24.36. The stock had a trading volume of 202,650 shares, compared to its average volume of 551,138. The firm’s 50-day moving average price is $23.68 and its two-hundred day moving average price is $21.81. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $44.91. The company has a market capitalization of $1.88 billion, a P/E ratio of -269.58, a P/E/G ratio of 0.73 and a beta of 1.17. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.11. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same period in the prior year, the company posted $0.89 earnings per share. Integra LifeSciences’s revenue for the quarter was up 11.5% on a year-over-year basis. Analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Insider Activity

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.10% of the stock is currently owned by insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.